Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by prophetoffactzon Mar 02, 2024 6:17pm
43 Views
Post# 35911518

RE:RE:Net Present Value

RE:RE:Net Present Value"Avalyn raised the amount however with a molecule already approved by the fda - their project is an enhanced delivery system for that molecule"

- Avalyn targets the lungs. CZO's treatment could be used outside the lungs too. Dr. Ask said delivery systems could be made. His presentation said 4/10 deaths worldwide are also due to fibrosis.

- COVID also wasn't around when Avalyn raised the C$80 million. McMaster was to investigate PGX-YBG with an anti-inflammatory already used for COVID patients according to a news release. Perhaps this could provide an accelerated path to approval compared to IPF.

- PGX-YBG can further be used as a delivery platform for the delivery of other drugs beyond fibrosis that target macrophages.  
<< Previous
Bullboard Posts
Next >>